



## Biofilm Inhibitors of Marine Origin

Guest Editor:

**Prof. Dr. Sadanandan E. E. Velu**

Department of Chemistry,  
University of Alabama at  
Birmingham, Birmingham, AL,  
USA

Deadline for manuscript  
submissions:

**closed (30 November 2019)**

### Message from the Guest Editor

Dear Colleagues,

Marine natural products have recently received increased attention as a source of lead compounds for drug discovery. Many of these compounds are anti-biofilm agents that may play a role in the field of antibacterial drug discovery. These compounds are identified based on bioactivity screens of marine natural products and their mode of action is generally unknown at the time of discovery. Discerning their mode of action is a critical step in their further development as potential drugs. This Special Issue focuses on such marine derived natural products or their analogs that are inhibitors or disruptors of biofilm. The coverage includes the biological activities of the lead compounds, discovery of their mode of action and their potential use in drug discovery. We aim to publish original research articles and review articles in this Special Issue.

Prof. Dr. Sadanandan E. Velu  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

## Contact Us

Marine Drugs Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
X@Marine\_Drugs